Drug Approvals
Nuvalent Has Made a Base Pattern on the Charts
This biopharmaceutical firm shows promise.
Here's My Prescription for Bristol-Myers Squibb
I'm bullish long term, but for now, can BMY generate follow-through buying?
Regeneron Soars But This Biotech ETF Is the Better Way to Get Exposure
Let's check the charts and indicators of the IBB.
A Technical Strategy to 'Buy' Agios Pharmaceuticals
Here's what aggressive traders could do now.
Lilly Disappoints All Around But Here's When I Would Invest
This stock is in a technical state of weakness and add that to the eroding fundamentals.
Allogene Therapeutics' Charts Suggests a Rally Ahead
Here's how traders can play the stock.
Incyte's Setup Should Inspire Bullish Traders
Buyers of the biopharmaceutical's stock are being more aggressive than sellers.
Cytokinetics Is Showing Its Muscles on the Charts
In light of the stock market's weakness, CYTK has shown impressive strength.
Enanta Pharmaceuticals Bounces Off a Key Support Level Once Again
The shares of the biotech company appear to be finding a bottom but could use more sideways action to create a better base.
As Biotechs Seem to Have Bottomed, Here Are 3 to Consider
I expect biotech M&A activity to pick up in the back half of 2022.